| 查看: 1379 | 回复: 17 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
开发一种新药的惊人花费（The truly staggering cost of inventing new drugs）
|
|||
|
原文链接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回复此楼» 猜你喜欢
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有165人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
生防菌的盆栽防效实验
已经有1人回复
-
请教大佬扩散问题
已经有5人回复
-
跪求一支AAV293细胞
已经有1人回复
-
中文投稿“肿瘤免疫”相关
已经有6人回复
-
2025年药学专业求调剂
已经有1人回复
-
292药学调剂
已经有1人回复
» 抢金币啦！回帖就可以得到:
-
2026年赣南师范大学 电子科学与技术专业（学硕）+ 电子信息工程（专硕）接收调剂学生
+1/195
-
山东建筑大学 （市政与环境工程学院）硕士研究生招生啦 静电纺丝纤维与盐水分离应用
+1/88
-
青岛大学固态电池研究团队招收材料、化学、物理等方向博士研究生
+2/46
-
中国石油大学（北京）国家级大人才团队博士招生1名：化学、材料、石油工程：油田化学
+1/38
-
中国计量科学研究院长度量子基准实验室2026年调剂招生
+1/34
-
【211博士招生】环境化学、地学、毒理方向，擅长污染物迁移转化降解、计算模拟者优先
+1/33
-
南京林业大学-国家级青年人才团队 招2026级博士、硕士（合成化学、植物化学方向）
+1/20
-
08开头有调剂需求的同学
+3/19
-
广东唯一石化院校——资源与环境专硕招生
+1/12
-
中国地震局地质研究所+地球物理专业+接收调剂
+1/11
-
武汉工程大学资源生物技术课题组生物/环境/化工/矿冶专业硕士、博士研究生招生及调剂
+1/9
-
【博士招生】天津理工大学国家杰青王铁课题组招收2026年博士研究生
+1/9
-
博士招生 | 青岛科技大学（高分子、化学、材料、力学、机电工程、计算机仿真）
+1/9
-
中国地质大学（北京)工程技术学院安老师组招收2026调剂生
+1/9
-
【博士招生】天津理工大学国家杰青王铁课题组招收2026年博士研究生
+1/8
-
墨子实验室理论计算和模拟研究组诚聘海内外优秀人才
+1/7
-
双非有经验之人求调剂
+1/5
-
上海交大招收26年级秋季入学博士生，CET-6过，生物医用材料方向（有高分子合成基础）
+1/4
-
福建师范大学国家级人才团队招收2026年博士研究生
+1/4
-
武汉理工大学船海与能源动力工程学院刘鹏飞院士团队博士后招聘启事
+1/4
9楼2015-09-01 08:14:29
7楼2015-08-31 16:02:44
10楼2015-09-01 08:19:15
11楼2015-09-14 11:50:36
